Coeptis Therapeutics Holdings (COEP) has released an update.
The Company has updated its risk factors to reflect its non-compliance with Nasdaq’s minimum bid price requirement, risking the delisting of its common stock from The Nasdaq Capital Market, which could have severe consequences on its business and stock liquidity. They received a notice of non-compliance and have until July 29, 2024, to meet the requirements. Failure to regain compliance could lead to delisting, with the possibility to appeal. Delisting could result in the stock being quoted over-the-counter, reduced liquidity, classification as a “penny stock,” and limited access to financing.
For further insights into COEP stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
